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This article explores the complexities of introducing new contra­
ceptive technologies and applies these to the initiation of the 
subdermal contraceptive implant (implant) in the South African (SA) 
context. Using the World Health Organization (WHO)’s conceptual 
framework[1,2] and other emerging literature, lessons are identified 
and key recommendations proposed. 
Over the past decade there have been concerted efforts to promote 
long­acting reversible contraceptive (LARC) methods in sub­Saharan 
Africa, especially the implant and the copper intrauterine device 
(IUD).[3,4] These methods have high continuation rates compared 
with other methods and very high effectiveness (<1 unintended preg­
nancy per 100 women­years).[5] It is estimated that almost 2 million 
unintended pregnancies could be averted over 5 years if only 20% of 
women in sub­Saharan Africa, currently using shorter­acting methods 
(oral contraceptives or injectables), switched to the implant.[6] In this 
region, the contraceptive method mix has long been dominated by 
these shorter­acting methods, which, when used correctly, are highly 
effective and acceptable to women. However, these methods are also 
associated with significant rates of discontinuation, incorrect use, 
poor adherence and consequent unintended pregnancy.[7] Similarly, 
SA’s most commonly used contraceptive methods are the injectables,[8] 
depot­medroxyprogesterone acetate (DMPA) and norethisterone 
enanthate (NET­EN), which account for half of contraceptive use 
nationally.[9,10]
The implant is registered for use in more than 100 countries 
worldwide,[11] including many in sub­Saharan Africa, where use has 
increased rapidly over the past decade.[12,13] In 5 years, uptake doubled 
in Malawi, quadrupled in Tanzania, and rose more than 15­fold in 
Rwanda and Ethiopia.[12,14,15] In Zimbabwe, for example, implant 
use increased from <1% in 1994 to 10% by 2015.[16] In 2014, SA 
introduced the implant – somewhat later than other countries in 
the region – in an effort to expand its method mix and especially to 
increase access to LARCs, which have been given centre place in the 
country’s contraception policy.[17,18] Aside from the effectiveness of 
LARC methods and the benefits of increasing method choice,[19,20] 
the possible links between injectables (particularly DMPA) and 
risk of HIV acquisition provided an impetus for the introduction of 
alternative methods in SA.[18,21,22]
The launch of the implant in SA was accompanied by much 
excitement and anticipation – it was the first new method introduced 
in the public sector in almost 20 years. Implant services were described 
as ‘the biggest family planning programme SA has ever seen’,[23] with 
≥6 000 healthcare providers trained with regard to implant provision, 
with a focus on insertion. Both the 5­year, two­rod levonorgestrel 
implant (Jadelle) and the 3­year, single­rod etonogestrel implant 
(Implanon NXT) were registered with the SA Medicines Control 
Council for use, but only Implanon NXT was made available in public 
health clinics as part of the national contraception programme. 
Estimates of implant uptake in the year after launch ranged from 
176 000, based on data reported to the District Health Information 
System (DHIS), to as high as 900 000, according to the Department of 
Health.[24,25] Data from the subsequent years, however, showed an almost 
50% decrease in insertion numbers year on year.[26] The number of 
insertions dipped considerably across all districts that reported these data 
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In 2014, South Africa (SA) introduced the subdermal contraceptive implant with the aim of expanding the contraceptive method mix and 
availability of long­acting reversible methods in the public sector. Three years on, concerns have been raised about the decline in uptake, early 
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elsewhere and applies these to the SA context. Drawing on the World Health Organization’s conceptual framework for the introduction of new 
contraceptive methods, and subsequent literature on the topic, lessons are classified into six cross­cutting themes. Recommendations highlight 
the need for SA to review and explore strategies to strengthen current implant services, including the provision of improved provider training 
aimed at sensitive, client­centred approaches; increased community engagement; and improved systems for programmatic monitoring and 
evaluation. With implementation of these recommendations, worrying trends in the provision of implants could be reversed. 
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(Table 1, Fig. 1). The Demographic and Health Survey (2016) estimated 
im plant use at 8% for married and sexually active unmarried 
women.[10] Actual numbers of removals are not known, because these 
were not initially systematically recorded. However, some reports 
in the media suggested that early removals were common and that 
women faced difficulties in getting implants removed because of 
healthcare­provider resistance to removal.[27,28] Therefore, while the 
introduction of the implant heralded an important step towards 
the strengthening of SA’s contraception programme, and brings 
the country on par with its regional counterparts in terms of wider 
method choice, SA’s implant programme is facing several challenges. 
Many of these challenges are common to the introduction of new 
contraceptive technologies elsewhere. On occasion, the roll­out 
of a new contraceptive method has been undermined by adverse 
events and negative user experiences related to inadequate quality 
of care, which even if uncommon, have resulted in adverse publi­
city, rumours and misperceptions. It is, therefore, timely and critical 
to reflect on lessons learnt from the early period of implant avail­
ability in SA, based mainly on the experiences and insights of the 
authors, all of whom are closely involved in the SA contraception 
programme. These lessons are placed in the context of similar expe­
riences of contraceptive introduction elsewhere. We classify these 
findings into six thematic areas, drawing on a WHO conceptual 
framework for the introduction of a contraceptive method,[1,2] as 
well as subsequent literature on the topic.[29­33] We then propose key 
steps that could reinforce and reconfigure the implant programme 
in SA. 
Lessons learnt – six thematic areas
1. Learn from the ‘boom-and-bust’ phenomenon in 
family planning 
The term ‘boom­and­bust’ in family planning describes the pheno­
menon in which there is an initial boom in the use of a new contra­
ceptive technology, coupled with excitement and optimism, followed 
by a rapid downturn due to unmet expectations and disappointment 
– the ‘failed promise of the contraception revolution’.[33] Several 
contraceptive methods have had a particularly turbulent history, as 
summarised in Box 1. Concerns have been raised about the potential 
for the implant to follow a similar trajectory if lessons from the past 
are not heeded.[15]
Importantly, the boom­and­bust phenomenon in family planning 
can have far­reaching, long­term, negative consequences, creating 
a climate of mistrust and lack of confidence in a method, or 
even in family planning services, more broadly. These effects may 
be experienced many years afterwards – for both providers and 
consumers – and may result in withdrawal of the method.[2]
The boom­and­bust concept explicitly acknowledges the impor­
tance of closely monitoring the introduction of a new method, and 
then swiftly recognising and addressing the causes of any downward 
turn in uptake or acceptability more generally. Accurate data on 
uptake, pharmacovigilance, and levels of discontinuation or removal 
and reasons thereof are especially important. 
2. Promote informed choice
In the enthusiasm of introducing a new, promising contraceptive meth­
od, there may be a tendency to promote that method over others,[2,7,37] 
both programmatically and at the level of individual provider­client 
interactions. This bias, which may be overt or subtle, may result in the 
provision of incomplete information and counselling, the over­selling 
Table 1. Contraception methods dispensed, 2013/2014 - 2015/2016[26] 
Type of contraceptive 
dispensed
2013/2014 2014/2015 2015/2016 Change 2014/ 
2015 - 2015/ 
2016, %n
Contraceptive 
years dispensed n
Contraceptive 
years dispensed n
Contraceptive 
years dispensed
Female condoms 13 254 328 66 271 21 099 517 105 497 27 005 805 135 029 28
IUD inserted 41 817 167 268 39 168 156 672 15 150 60 600 ­61.3
Male condoms 506 431 299 2 532 156 712 387 234 3 561 936 839 874 751 4 199 373 17.9
Medroxyprogesterone 5 762 721 1 440 680 5 510 430 1 377 607 5 578 228 1 394 557 1.2
Norethisterone 
enanthate
4 277 194 712 865 3 834 005 639 000 3 676 445 621 740 ­4.1
Oral pill cycles 3 815 539 293 503 3 560 421 273 878 3 591 382 276 260 0.9
Sterilisation female 31 551 631 020 32 074 641 480 33 134 662 681 3.3
Sterilisation male 1 120 11 200 877 8 770 772 7 720 ­12
Subdermal implant 
inserted
­ ­ 175 948 527 844 87 189* 261 567 ­50.4
Total ­ 5 854 963 ­ 7 292 684 ­ 7 619 527 4.4
IUD = intrauterine device.
*Subdermal implants for 2015 ­ 2016 were reported by only four provinces.
Fig. 1. Implant insertions in SA by province (April 2014 - March 2017).[26] 
(No data are available for the Eastern Cape, the Free State, Mpumalanga, 
North West and the Western Cape before April - June 2015.)
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of the benefit of the new method, a lack of acknowledgment that each 
contraceptive method comes with advantages and disadvantages, and 
that the importance of these differ from person to person. Within the 
early stages of the implant programme in SA, concerns arose that con­
traceptive users were not being given an adequate choice of methods, 
with the implant being strongly promoted as the first­line method, and 
with insufficient counsel ling about possible side­effects or alternative 
contraceptive options. 
3. Avoid over-emphasis of method technology and 
technological advantages
A focus on technological advantages of the implant, e.g. its long­
term action, high efficacy and cost­effectiveness, may overshadow a 
woman’s personalised experience of the method, especially the impact 
and tolerability of side­effects. Most importantly, a preoccupation 
with the long-acting dimensions of the LARCs can result in pre­
eminence being given to the continuation rate as the indicator of 
success and acceptability. If that occurs, then early removal is seen as 
problematic and even as wasteful, and may generate resistance among 
healthcare providers to performing early removals.[31] 
In SA, an over­emphasis on the notion of ‘3 years of use’ perhaps 
has meant that the programme did not adequately anticipate and 
prepare for early removals, as these were viewed as signalling a failure 
of the programme rather than merely a reflection of the varying 
needs of women over time, which is to be expected and should be 
planned for. Implant removals are common across all settings. For 
example, about a quarter of women discontinued within the first year 
of use in studies in the Netherlands,[38] the UK and Australia,[39,40] as 
well as other settings.[14,15] Also, the reality of early removal levels may 
not always match perceptions, e.g. in Ethiopia concerns arose about 
early removals, but an evaluation showed that only ~2% of implant 
users had discontinued the method by 6 months.[41] 
It is important to keep implant removals in perspective – because 
the implant requires healthcare­provider intervention for removal, 
providers generally hear of and see women who are dissatisfied with 
the method and/or who request removals, and not the many ‘silent’ 
women who are satisfied with the method and only return to the 
clinic after 3 years. Furthermore, healthcare providers are generally 
not accustomed to having to actively manage discontinuation of 
contraceptives. Women discontinue pills or injections on their own, 
contributing to the perception that there is a higher rate of implant 
discontinuation compared with other methods. 
Conceptually, thinking and language need to move away from the 
notion that the implant is designed to be used for a certain number 
of years, to the more nuanced message that it can be used for a 
number of years if women choose to do so.[1,31,42] Key to improving 
implant provision is understanding the reasons for early removals, 
e.g. are these due to inadequate counselling; dissatisfaction with the 
method; lack of support while using the method, including assistance 
in dealing with side­effects; or women no longer being sexually active 
or wanting to become pregnant?
4. Focus on quality standards and overall access, rather 
than targets for an individual method
Internationally, it is common practice to make contraceptive 
programmes heavily target driven, and although this is often well 
intentioned, it may compromise quality of care.[15] An example is 
target setting for training, which occurred in SA, with a focus on 
numbers of providers trained, rather than on quality of training and 
documenting provider proficiency outcomes. The number of devices 
inserted is also often target driven, and can occur at the expense of 
oversight of the quality of care provided.[42,43] While there are merits 
to setting targets, e.g. around overall contraceptive prevalence in a 
country, indicators need to centre around access, which includes 
dimensions such as quality of services and client satisfaction, rather 
than merely uptake. 
5. Adoption of innovative, acceptable and comprehen-
sive service-delivery models
Innovative models of service delivery warrant consideration, drawing 
on experiences from other settings. For example, the use of dedicated, 
specially trained providers might be more appropriate where new 
clinical skills, such as implant removals, are difficult to roll out to 
large numbers of providers. In 2008 ­ 2009, Zambia trained 18 retired 
midwives and deployed them to high­volume, public­sector facilities, 
solely for the provision of LARC services over 14 months, which 
showed a marked increase in uptake over a short period of time.[14,44]
A key challenge for implant service delivery is getting the balance 
right in relation to training on insertions and removals. The pattern 
of introducing implants and focusing training on insertions and not 
Box 1. Boom-and-bust of contraception methods
• The Lippes Loop IUD, introduced in 1960, was aggressively promoted in India, with ‘loop squads’ and cash incentives, and >2 million 
insertions were done between 1965 and 1967.[34] Very high levels of early removal have been mostly attributed to over­zealous persuasion 
of women to use the IUD, with little attention to method choice, counselling about method disadvantages, and possible side­effects, e.g. 
bleeding and cramping. The India Family Planning Programme also failed to address widespread rumours, misconceptions and cultural 
issues relating to the device.[34] The shortcoming of the Lippes Loop introduction negatively impacted IUD use in India for many years.[1,35]
• The Dalkon Shield IUD, which was introduced as a ‘safe’ alternative to the oral contraceptive pill in the 1970s, was the target of legal 
action in the USA, and the subject of extensive negative publicity, and was ultimately removed from the market. While removal of the 
device was justified, as it was determined that a structural flaw in the device caused septic abortions and pelvic infections, this controversy 
contributed to negative perceptions about safer, new­generation IUDs, and is partially responsible for the lingering, even though now 
disproven, concerns about IUDs causing pelvic inflammatory disease.[36] This experience highlights the need to invest effort in debunking 
misconceptions and providing correct information. 
• Another example is provided by Norplant. This six­rod subdermal progestin­only implant, was seen as a major breakthrough in 
contraceptive technology when it was introduced in several countries, including the USA, UK and Indonesia, in the 1990s. Accusations of 
failure of the manufacturer to disclose side­effects led to litigation in the USA. Although the litigation was ultimately unsuccessful, it was 
accompanied by negative publicity and, along with problems in other countries, contributed to Norplant’s withdrawal from the market 
in 2006.[29] Other problems with Norplant related to quality of care, including mass insertions, called ‘safaris’ in Indonesia, leading to 
perceptions of client coercion;[30] inadequate provider training and lack of competency in insertion and removal; accusations of healthcare­
worker resistance to removal; and poor­quality counselling.[31]
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on removals, has repeated itself across countries.[14,19] This approach 
is based on the assumption that there would be a window of several 
years in which to do this training. Also, practically, it is difficult 
for healthcare providers to learn how to perform removals at the 
onset of a programme, when few insertions have been made. Often, 
there is intent to do training on removals, but once the implant is 
introduced the momentum for training dissipates. Clearly, access to 
quality removal services from the onset of an implant programme 
is essential. Many countries have underestimated the number of 
women who would request removals before 3 years.[14,15] Failure to 
provide accessible removal services is an infringement of women’s 
rights, and may impact negatively on the community’s perception 
of the implant. 
Expanding the choice of contraceptive methods does not necessarily 
result in increased utilisation if constraints in the health system and 
the needs of the end user are not taken into account.[2,31] A holistic 
perspective is called for, tailored to the social, cultural, and personal 
norms and values that influence patterns of use in a particular context. 
Such a perspective explicitly acknowledges that the implant is most 
often used by healthy women, who may not be willing to accept side­
effects,[37,45] many of which are genuinely uncomfortable.[2,14,45] 
The needs of women also change with age. Of note, adolescents 
have specific considerations, which are best met within the context 
of youth­sensitive services.[46­48] Little has been done to promote the 
implant among SA adolescents, with a commonly held perception 
that the method is more suitable for adults. Several studies, however, 
show that the implant is highly acceptable to young women,[49,50] with 
continuation rates of ~80% after 12 months,[51] including in studies in 
sub­Saharan Africa.[52] 
Lastly, the importance of demand creation, community engage­
ment, sensitisation and addressing of concerns as they relate to 
a woman’s life and context requires emphasis.[53] This involves 
genera ting a dialogue and structured engagement with programme 
planners, health workers, communities and end users to identify and 
address barriers.[14,32,53] Non­governmental organisations, researchers 
and technical assistance agencies could all make an important 
contribution to such efforts. 
6. Ensure a rights-based approach
The abovementioned lessons draw together important strands, which 
locate the promotion of the implant within the context of sexual 
and reproductive health and rights.[13,54­57] A rights­based approach 
is especially important given that, historically, family planning 
program mes in SA have been associated with coercion.[58,59] 
Most importantly, services must take into account the gamut of 
social, cultural and relational factors that influence contraceptive 
uptake and continued use. Each new method carries a set of 
trade­offs for healthcare systems, providers and end users that will 
influence acceptability and continued use.[2] Therefore, options­
based, rather than directive counselling, is required, so that the 
implant is not recommended above other methods. Effectiveness 
is only one of many criteria that determine the optimum method 
for a woman at a particular point in time, and other factors may 
guide her choice, including how frequently she has sex, her partner’s 
involvement, her fertility desires, and cultural or personal issues 
relating to side­effects. Sensitivity and attention to these dimensions 
ensure that clients are informed and have agency regarding method 
selection, and continuing or discontinuing use. 
Recommendations
Based on the lessons described above, we propose the following 
priority recommendations to support SA’s implant programme:
Capacity building for healthcare providers 
• The expanded provision of new and refresher training courses for 
healthcare providers, which cover technical skills around insertion 
and removal, informed decision­making and choice for women, 
pre­insertion counselling, especially around side­effects, and long­
term support and management of side­effects. 
• Capacity building needs to strengthen provider confidence and 
competence in insertions and removals, recognising that this 
requires an investment in quality training, effective supervision, 
structured mentorship and accessible on­site support.
• Training and support need to include more nuanced counselling, 
which should address issues such as changes in bleeding patterns 
and how this may affect women’s lives, e.g. the cost of sanitary wear 
and sexual relationships. Reassurance and competent management 
of side­effects play a major role in determining whether a woman 
chooses to continue the method.
• A skills and human resource assessment needs to be done, espe­
cially in relation to implant removals, and measures should be put 
in place to address gaps. 
• Training needs to focus on the most recent WHO medical eligi­
bility criteria guidance for the implant, in particular the suitability 
of implants for women of all ages, including adolescents, and 
highlight potential advantages of the method for this group.
Clear communication to healthcare providers and end 
users regarding drug interactions
• Clear communication needs to be provided for both healthcare 
providers and end users where drug interactions might be a potential 
problem, including for those on treatment for tuberculosis (TB), HIV 
or epilepsy.[60,61] In the presence of ambiguity, healthcare providers 
understandably err on the side of caution, either not offering implants 
to potentially eligible women or unnecessarily encouraging removal.
Data collection and monitoring systems
• Address data gaps in recording of uptake, removals and pharmaco­
vigilance, including use of the implant in women with medical 
conditions such as epilepsy, HIV and TB. 
• Disaggregate implant data by age (especially to identify use among 
adolescents and young women) and by specific groups of women, 
such as postpartum and post­abortion patients. This can then be 
used to identify gaps in provision, training, quality of care, and 
factors influencing uptake and continuation.
Increase demand
• Adopt innovative service­delivery models, which could include 
‘re­introducing’ the implant (and other LARC methods, such as 
the IUD) in selected districts; engage with communities in terms of 
myths, misconceptions and women’s experiences with the method; 
and debrief healthcare providers about their experiences with the 
method and their concerns.
Assess the feasibility of further expanding the 
contraceptives available in the public sector
• Contraceptive use may be increased by expanding the range of 
methods available to accommodate different needs.[20] The SA 
contra ception policy recommended a 5­yearly review (2012 
­ 2017).[17,62] This is now imminent and presents a window of 
opportunity to review the guidelines. More specifically, based 
on the concerns raised in this article, the review should consider 
uptake of and barriers to the use of all methods. With the 
emergence of new data, further consideration should be given to 
different contraceptives among women at risk of HIV and those 
937       November 2017, Vol. 107, No. 11
CME
infected with HIV or TB, including guidance on contraceptive 
prescribing and drug interactions. 
Conclusion 
Problems and challenges encountered during the introduction phase 
of the contraceptive implant in SA are not unique, and mirror 
experiences elsewhere. Lessons learnt elsewhere provide valuable 
insights about the health­system elements required to support service 
provision and demand creation, as well as ensuring that these take 
place within a rights­based framework. It is critical to heed these 
lessons, identify and analyse problems and deal with them effectively 
to ensure success of implant introduction. 
Real or perceived concerns about new methods, such as the 
implant, may discredit the use of methods by current and potential 
users, communities and healthcare providers. It is imperative that 
the potential contribution of the implant to women’s health in 
SA is not undermined by unsubstantiated negative publicity and 
misconceptions, or by the unwarranted importance assigned to 
removal rates not supported by data.
Addressing the skewed contraceptive method mix in SA and 
promoting a greater choice of methods, including the implant, 
require nuanced provider training and sensitivity, novel health­system 
support, intensive community engagement, consumer awareness, 
and systems for programmatic monitoring, evaluation and quality 
improvement. While this article specifically addresses issues relating 
to implants, many of these reflections may apply to the strengthening 
of other LARC methods, such as the IUD, and indeed, the contracep­
tive programme as a whole.
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